Quantcast
Home > Quotes > OGEN
x

Oragenics Inc. Common Stock (OGEN) Quote & Summary Data

OGEN 
$1.2827
*  
0.1427
12.52%
Get OGEN Alerts
*Delayed - data as of Oct. 17, 2018 12:22 ET  -  Find a broker to begin trading OGEN now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    OGEN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
5
Today's High / Low
$ 1.42 / $ 1.22
Share Volume
7,670,355
90 Day Avg. Daily Volume
4,848,253
Previous Close
$ 1.14
52 Week High / Low
$ 4.712 / $ 0.38
Market Cap
37,401,140
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.8

Intraday Chart

Shares Traded

Share Volume:
7,670,355
90 Day Avg. Daily Volume:
4,848,253

Trading Range

The current last sale of $1.2827 is 237.55% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.42 $ 4.712
 Low: $ 1.22 $ 0.38

Company Description (as filed with the SEC)

This description contains certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein. We assume no obligation to update any forward-looking statements contained herein. Overview We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Our Oral Mucositis Product Candidate-Clinical In June of 2015, we entered into a worldwide Exclusive Channel Collaboration Agreement ("Oral Mucositis ECC") with Intrexon Corporation ("Intrexon") and Intrexon Actobiotics NV, a wholly-owned subsidiary of Intrexon, pursuant to which we obtained certain exclusive rights to AG013 as a potential treatment of oral mucositis, or OM for cancer patients, which we intend to continue to develop.  ... More ...  

Research Brokers before you trade

Want to trade FX?

Analyst Info